Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Variation of uptake of anti-CEA monoclonal antibody with tumor type and mass

Conference · · J. Nucl. Med.; (United States)
OSTI ID:6706575
A nude mouse model xenografted with 3 human tumor (T) was studied with an anti-carcinoembryonic (..cap alpha..-CEA) monoclonal antibody (MoAb). The MoAb was labeled with In-111 using a bi-functional chelation technique. In vitro cross-reactivity with human blood (B) and liver (L) cells was minimal. Human colon tumors were WIDR, SW403 an LS174T. The murine carcinoma EMT6 was used as a control. In all cases only 62.5 ngm of ..cap alpha..-CEA charged at 10 ..mu..Ci/..mu..gm was given to each animal. The corresponding value in humans, 200 ..mu..gm, is probably subimmunogenic. Organ distribution in percent injected dose/gm (% ID/gm) and images were obtained at 48 h post-injection of the MoAb. CEA levels (mgm/gm of T) were measured for each tumor using the same MoAb (T 84.66). Variation of % ID/gm with LS174T mass (m) was also determined. Uptake by EMT6 was 2.4 +- 0.2 % ID/gm. LS174T uptake varied approximately as the inverse of tumor mass. The authors conclude that tumor accumulation of ..cap alpha..-CEA MoAb is not directly correlated with the amount of CEA in the lesion. The best uptake, T/B and T/L values occurred with LS174T; this was also borne out by the 48 h images. Because of the smaller average SW403 mass, this result cannot readily be explained as a tumor size effect.
Research Organization:
City of Hope Medical Center, Los Angeles, CA
OSTI ID:
6706575
Report Number(s):
CONF-850611-
Conference Information:
Journal Name: J. Nucl. Med.; (United States) Journal Volume: 26:5
Country of Publication:
United States
Language:
English